What Has the FDA Specifically Warned About Regarding Fraudulent Compounded Semaglutide and Tirzepatide?
What has the FDA specifically warned about regarding fraudulent compounded semaglutide/tirzepatide products?
Published September 2, 2026
Key takeaways
- The FDA has documented compounded semaglutide and tirzepatide products sold with false label information, including compounding pharmacy names that don't exist or weren't actually involved.
- The FDA has issued individual warning letters to specific named companies — including MEDVi, Medica Weight Loss, and GLP-1 Solution — over marketing and labeling of compounded GLP-1 products; these are public, dated, and independently checkable documents.
- At least one documented adverse event (injection site redness, swelling, pain, and a lump) was tied to a product falsely labeled as coming from a pharmacy that hadn't compounded it.
- The practical defense is the same one that applies everywhere else in this space: confirm the pharmacy named on your prescription actually exists and actually fills your specific order — don't take a label at face value.
Mazrek
Physician-reviewed GLP-1 care
- State-licensed compounding pharmacy partner
- Certificate of analysis provided per batch
- Every prescription reviewed by a licensed provider
- Unlimited care team messaging
Prescription required. Treatment is only provided if clinically appropriate, as determined by a licensed provider.
The specific pattern the FDA has documented
This isn't a general "be careful" warning — the FDA has described a specific fraud pattern with compounded GLP-1 products: labels that name a compounding pharmacy, where that pharmacy either doesn't exist, or exists but had nothing to do with making that particular product. In practice, that means a patient could receive an injectable medication with no real accountability behind who actually prepared it.
The FDA has also documented a related, separate problem: dosing errors in compounded semaglutide products, including cases where patients were dosed beyond FDA-approved label ranges.
What this actually caused
This isn't hypothetical. The FDA has reported an adverse event tied to a product labeled as coming from a compounding pharmacy that did not actually compound it — the reported symptoms were injection site redness, swelling, pain, and a lump. That's a concrete example of what "the label lied about who made this" can mean for a patient using the product.
Named, dated, checkable warning letters
Rather than a general statement, the FDA has issued specific, public warning letters to named companies over compounded GLP-1 marketing and labeling — for example, letters to MEDVi (February 2026), Medica Weight Loss (June 2026), and GLP-1 Solution (September 2025). These are official FDA documents, individually dated and posted on FDA.gov — you can read the specific findings in each one rather than relying on a paraphrase.
How to protect yourself from this specific pattern
Since the documented problem is specifically about labels misrepresenting the compounding pharmacy, the defense is specific too: don't just read the pharmacy name on your label or website — confirm it independently. Look the pharmacy up with its state board of pharmacy, and if you can, confirm with your provider that this named pharmacy is the one actually filling your specific prescription, not just a name printed on marketing material.
Frequently asked
What exactly does it mean for a product label to be 'fraudulent'?+
In the cases the FDA has documented, it means the label named a compounding pharmacy that either doesn't exist, or exists but did not actually compound that specific product. The label is presenting false information about who made the medication and under what oversight.
Has this actually caused a documented health problem, or is it a theoretical risk?+
It's documented, not theoretical. The FDA has reported at least one adverse event — injection site redness, swelling, pain, and a lump — tied to a product labeled as coming from a compounding pharmacy that had not actually made it.